Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Calithera Drops Development Of Lead Candidate Telaglenastat

Interim Phase II Lung Cancer Data Underwhelming

Executive Summary

Calithera’s most advanced oncological asset, telaglenastat, has failed in yet another indication, prompting the company to fall back on candidates in-licensed from Takeda just last month.

You may also be interested in...



Asia Deal Watch: I-Mab Partners With Sinopharm As It Readies First Regulatory Filing

I-Mab sets commercial plans with Sinopharm for felzartamab in multiple myeloma. Legochem and Antengene team up on antibody-drug conjugates, Luoxin licenses respiratory drug from Marinomed.

Engitix Collaborates With Dompé On Fibrosis And Cancer As It Eyes The Clinic

The UK biotech has struck up an unusual deal with its new investor that lets it retain control over its assets, as it raises $54m in a series A.

‘Bugs As Drugs’ Approach To Cancer Nears Advanced Development

Microbiome modulators, known mainly for development in infectious and gastrointestinal diseases, could prove an asset in oncology thanks to the work of biotechs.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145369

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel